Scientists report on testing of an experimental Ebola vaccine called VSV-EBOV that appears safe and elicited a robust immune response in a small phase 1 clinical trial, according to be published in the New England Journal of Medicine on April 2, 2015.
Two independent but coordinated studies, performed at the Walter Reed Army Institute of Research (WRAIR) and the National Institute of Allergy and Infectious Diseases (NIAID), explored the safety and immunogenicity of the investigational vaccine when administered at different dosages.
“These pivotal early studies helped inform dose selection for testing of VSV-EBOV vaccine in a large-scale clinical trial in West Africa,” noted Lt. Col. Jason Regules at WRAIR, one of the two co- lead authors of the paper. “We were gratified to see that the vaccine was not associated with significant adverse effects in this very carefully monitored study,” Regules added.
Scientists at the Public Health Agency of Canada’s National Microbiology Laboratory originally developed the VSV-EBOV vaccine candidate, one of two Ebola vaccines currently in large scale testing in West Africa. It has been licensed to NewLink Genetics Corp. in collaboration with Merck Sharp & Dohme Corp (Merck). The Ebola genetic material of the Ebola virus coat is delivered by a carrier virus (recombinant Vesicular Stomatitis Virus, or rVSV). The candidate vaccine does not contain Ebola virus and cannot cause Ebola virus disease.
The trials collectively enrolled 52 volunteers who received either the vaccine candidate or a placebo. Those volunteers given the vaccine received one of two different doses and volunteers were assessed on days 1, 3, 7, 14, and 28 to see if they developed anti-Ebola antibodies.
Twenty-six of 28 volunteers (93%) in the vaccine group showed the intended Ebola glycoprotein antibody response within two weeks of vaccination, and all of the volunteers had antibodies within 28 days of receiving the vaccine. Researchers saw a higher antibody response in the vaccine recipients who received the higher vaccine dose.
“We saw a robust immune response following a single dose of the vaccine, which could be particularly useful in outbreak interventions,” said Col. Stephen Thomas, WRAIR’s Deputy Commander and senior author on the paper. NIAID researchers are also looking at effects of an extra boost of the vaccine at day 28; results are expected later this year.
This clinical trial began in October during the peak of the devastating Ebola outbreak in West Africa. The combined experience of WRAIR and NIAID with Ebola and other infectious diseases, to include the conduct of human clinical trials, enabled an agile shift in resources towards prioritizing the Ebola vaccine trial in just 11 weeks. All partners took part in developing the necessary assays to characterize vaccine safety and immune response. Critical support was provided by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and the DoD Chemical Biological Defense Program.
“This is an example of the whole of government working at its best to address a public health issue,” said Col. Thomas. “We were able to leverage the WRAIR’s experience in conducting ethical and safe clinical research experiments to meet a global need.”